Schizophrenia

For other uses, see Schizophrenia (disambiguation).

Schizophrenia
Specialty	Psychiatry, clinical psychology

Schizophrenia (Template:Pron-en or /ˌskɪtsɵˈfriːniə/) is a mental disorder characterized by a disintegration of the process of thinking and of emotional responsiveness. It most commonly manifests as auditory hallucinations, paranoid or bizarre delusions, or disorganized speech and thinking, and it is accompanied by significant social or occupational dysfunction. The onset of symptoms typically occurs in young adulthood, with a global lifetime prevalence of around 0.3–0.7%. Diagnosis is based on the patient's self-reported experiences and observed behavior.

Genetics, early environment, neurobiology, psychological and social processes appear to be important contributory factors; some recreational and prescription drugs appear to cause or worsen symptoms. Current research is focused on the role of neurobiology, but this inquiry has not isolated a single organic cause. As a result of the many possible combinations of symptoms, there is debate about whether the diagnosis represents a single disorder or a number of discrete syndromes. Despite the etymology of the term from the Greek roots skhizein (σχίζειν, "to split") and phrēn, phren- (φρήν, φρεν-; "mind"), schizophrenia does not imply a "split mind" and it is not the same as dissociative identity disorder—also known as "multiple personality disorder" or "split personality"—a condition with which it is often confused in public perception.

The mainstay of treatment is antipsychotic medication; which primarily works by suppressing dopamine activity. Dosages of antipsychotics are generally lower than in the early decades of their use. Psychotherapy, and vocational and social rehabilitation, are also important. In more serious cases—where there is risk to self and others—involuntary hospitalization may be necessary, although hospital stays are shorter and less frequent than they were in previous times.

The disorder is thought mainly to affect cognition, but it also usually contributes to chronic problems with behavior and emotion. People with schizophrenia are likely to have additional (comorbid) conditions, including major depression and anxiety disorders; the lifetime occurrence of substance abuse is around 40%. Social problems, such as long-term unemployment, poverty and homelessness, are common. Furthermore, the average life expectancy of people with the disorder is 12 to 15 years less than those without, due to increased physical health problems and a higher suicide rate (about 5%).

Signs and symptoms

A person diagnosed with schizophrenia may experience hallucinations (most commonly hearing voices), delusions (often bizarre or persecutory in nature), and disorganized thinking and speech. The latter may range from loss of train of thought, to sentences only loosely connected in meaning, to incoherence known as word salad in severe cases. Social withdrawal, sloppiness about dress and hygiene, and loss of motivation and judgement are all common in schizophrenia. There is often an observable pattern of emotional difficulty, for example lack of responsiveness or motivation. Impairment in social cognition is associated with schizophrenia, as are symptoms of paranoia; and social isolation commonly occurs. In one uncommon subtype, the person may be largely mute, remain motionless in bizarre postures, or exhibit purposeless agitation; these are signs of catatonia.

Late adolescence and early adulthood are peak years for the onset of schizophrenia. In 40% of men and 23% of women diagnosed with schizophrenia, the condition arose before the age of 19. These are critical periods in a young adult's social and vocational development. To minimize the developmental disruption associated with schizophrenia, much work has recently been done to identify and treat the prodromal (pre-onset) phase of the illness, which has been detected up to 30 months before the onset of symptoms, but may be present longer. Those who go on to develop schizophrenia may experience the non-specific symptoms of social withdrawal, irritability and dysphoria in the prodromal period, and transient or self-limiting psychotic symptoms in the prodromal phase before psychosis becomes apparent.

Schneiderian classification

The term Schizophrenia was coined by Eugen Bleuler

The psychiatrist Kurt Schneider (1887–1967) listed the forms of psychotic symptoms that he thought distinguished schizophrenia from other psychotic disorders. These are called first-rank symptoms or Schneider's first-rank symptoms, and they include delusions of being controlled by an external force; the belief that thoughts are being inserted into or withdrawn from one's conscious mind; the belief that one's thoughts are being broadcast to other people; and hearing hallucinatory voices that comment on one's thoughts or actions or that have a conversation with other hallucinated voices. Although they have significantly contributed to the current diagnostic criteria, the specificity of first-rank symptoms has been questioned. A review of the diagnostic studies conducted between 1970 and 2005 found that these studies allow neither a reconfirmation nor a rejection of Schneider's claims, and suggested that first-rank symptoms be de-emphasized in future revisions of diagnostic systems.

Positive and negative symptoms

Schizophrenia is often described in terms of positive and negative (or deficit) symptoms. The term positive symptoms refers to symptoms that most individuals do not normally experience but are present in people with schizophrenia. These symptoms gererally respond well to medication. They can include delusions, disordered thoughts and speech, and hallucinations such as tactile, auditory, visual, olfactory and gustatory and are typically regarded as manifestations of psychosis. Hallucinations are also typically related to the content of the delusional theme. Negative symptoms are symptoms that are altered or defect emotional responses that respond less successfully to medication. Common negative symptoms include flat or blunted affect and emotion, poverty of speech (alogia), inability to experience pleasure (anhedonia), lack of desire to form relationships (asociality), and lack of motivation (avolition). Research suggests that negative symptoms contribute more to poor quality of life, functional disability, and the burden on others than do positive symptoms. People with negative symptoms tend to respond less well to medication and can often have a history of poor adjustment before the onset of illness.

Causes

Main article: Causes of schizophrenia

A combination of genetic and environmental factors play a role in the development of schizophrenia.

Genetic

Estimates of heritability vary owing to the difficulty of separating the effects of genetics and the environment. The greatest risk for developing schizophrenia is having a first degree relative with the disease (risk is 6.5%) while more than 40% of monozygotic twins of those with schizophrenia are affected.

It is likely that many genes are involved each of small effect. Some have suggested that several genetic and other risk factors need to be present before a person becomes affected but this is still uncertain. Candidate genes linked to an increased risk of schizophrenia and bipolar disorder as found in recent genome wide association studies appear to be partly separate and partly overlapping between the two disorders Genetic linkage studies have produced evidence of chromosomal regions increasing susceptibility, which interacts directly with the Disrupted in Schizophrenia 1 (DISC1) gene protein more recently the zinc finger protein 804A. has been implicated as well as the chromosome 6 HLA region. However, a large and comprehensive genetic study found no evidence of any significant association with any of 14 previously identified candidate genes. Schizophrenia, in a small minority of cases, has been associated with rare deletions or duplications of tiny DNA sequences (known as copy number variants) disproportionately occurring within genes involved in neuronal signaling and brain development/human cognitive, behavioral, and psychological variation. Relations have been found between autism spectrum disorders and schizophrenia based on duplications and deletions of chromosomes; research showed that schizophrenia and autism are significantly more common in combination with 1q21.1 deletion syndrome, velo-cardio-facial syndrome and Phelan-McDermid syndrome. Duplications of parts of the chromosomes which are opposites of these syndromes show more autism-results. Research on autism/schizophrenia relations for chromosome 15 (15q13.3), chromosome 16 (16p13.1) and chromosome 17 (17p12) are inconclusive.

Assuming a hereditary genetic basis, one question for evolutionary psychology is why genes that increase the likelihood of the condition evolved, assuming the condition would have been maladaptive from an evolutionary/reproductive point of view. One theory implicates genes involved in the evolution of language and human nature, but so far all theories have been disproved or remain unsubstantiated.

Environment

A number of environmental factors are associated with the development of schizophrenia including prenatal stressors, the living environment, and drug use. Parenting style on the other hand has no effect on the risk. Living in an urban environment either during childhood or as an adult has been consistently found to increase the risk of schizophrenia by a factor of two. This is even after taking into account drug use, ethnic group and size of a persons social group. Other factors that play an important role include: social isolation and immigration related to social adversity, racial discrimination, family dysfunction, unemployment or poor housing conditions.

Substance abuse

A number of drugs have been associated with the developement of schizophrenia including: cocaine, amphetamines, and cannabis.

Cannabis use is statistically associated with a dose-dependent increase in risk of development of psychotic disorders, including schizophrenia. For example, cannabis use has increased dramatically in several countries over the past few decades, though contrary to predictions the rates of psychosis and schizophrenia have generally not increased.

Psychotic individuals may also use drugs to cope with unpleasant states such as depression, anxiety, boredom and loneliness, because drugs increase "feel-good" neurotransmitters level. Various studies have shown that amphetamines increases the concentrations of dopamine in the synaptic cleft, thereby heightening the response of the post-synaptic neuron. However, regarding psychosis itself, it is well understood that methamphetamine and cocaine use can result in methamphetamine- or cocaine-induced psychosis that present very similar symptomatology (sometimes even misdiagnosed as schizophrenia) and may persist even when users remain abstinent. The same can also be said for alcohol-induced psychosis, though to a somewhat lesser extent.

Prenatal

A number of factors during fetal development may result in a small increase in the risk of schizophrenia later in life including: hypoxia and infection, stress or malnutrition in the mother. People diagnosed with schizophrenia are more likely to have been born in winter or spring, (at least in the northern hemisphere). This may be due to the increased rates of viral exposures in utero.

Mechanisms

Main article: Mechanisms of schizophrenia

Psychological

A number of psychological mechanisms have been implicated in the development and maintenance of schizophrenia. Cognitive biases that have been identified in those with a diagnosis or those at risk, especially when under stress or in confusing situations, include excessive attention to potential threats, jumping to conclusions, making external attributions, impaired reasoning about social situations and mental states, difficulty distinguishing inner speech from speech from an external source, and difficulties with early visual processing and maintaining concentration. Some cognitive features may reflect global neurocognitive deficits in memory, attention, problem-solving, executive function or social cognition, while others may be related to particular issues and experiences.

Despite a common appearance of "blunted affect", recent findings indicate that many individuals diagnosed with schizophrenia are emotionally responsive, particularly to stressful or negative stimuli, and that such sensitivity may cause vulnerability to symptoms or to the disorder. Some evidence suggests that the content of delusional beliefs and psychotic experiences can reflect emotional causes of the disorder, and that how a person interprets such experiences can influence symptomatology. The use of "safety behaviors" to avoid imagined threats may contribute to the chronicity of delusions. Further evidence for the role of psychological mechanisms comes from the effects of psychotherapies on symptoms of schizophrenia.

Neurological Pathology

Data from a PET study suggests that the less the frontal lobes are activated (red) during a working memory task, the greater the increase in abnormal dopamine activity in the striatum (green), thought to be related to the neurocognitive deficits in schizophrenia.

Those with a diagnosis of schizophrenia have both changes in brain structure and brain chemistry. Studies using neuropsychological tests and brain imaging technologies such as fMRI and PET to examine functional differences in brain activity have shown that differences seem to most commonly occur in the frontal lobes, hippocampus and temporal lobes. Due to the alteration in neural circuits some feel schizophrenia should be viewed as a collection of neurodevelopmental disorders.These differences have been linked to the neurocognitive deficits often associated with schizophrenia.

Functional magnetic resonance imaging and other brain imaging technologies allow for the study of differences in brain activity among people diagnosed with schizophrenia

Particular focus has been placed upon the function of dopamine in the mesolimbic pathway of the brain. This focus largely resulted from the accidental finding that a drug group which blocks dopamine function, known as the phenothiazines, could reduce psychotic symptoms. It is also supported by the fact that amphetamines, which trigger the release of dopamine, may exacerbate the psychotic symptoms in schizophrenia. An influential theory, known as the Dopamine hypothesis of schizophrenia, proposed that excess activation of D₂ receptors was the cause of (the positive symptoms of) schizophrenia. Although postulated for about 20 years based on the D₂ blockade effect common to all antipsychotics, it was not until the mid-1990s that PET and SPET imaging studies provided supporting evidence. This explanation is now thought to be simplistic, partly because newer antipsychotic medication (called atypical antipsychotic medication) can be equally effective as older medication (called typical antipsychotic medication), but also affects serotonin function and may have slightly less of a dopamine blocking effect.

Interest has also focused on the neurotransmitter glutamate and the reduced function of the NMDA glutamate receptor in schizophrenia. This has largely been suggested by abnormally low levels of glutamate receptors found in postmortem brains of people previously diagnosed with schizophrenia and the discovery that the glutamate blocking drugs such as phencyclidine and ketamine can mimic the symptoms and cognitive problems associated with the condition. The fact that reduced glutamate function is linked to poor performance on tests requiring frontal lobe and hippocampal function and that glutamate can affect dopamine function, all of which have been implicated in schizophrenia, have suggested an important mediating (and possibly causal) role of glutamate pathways in schizophrenia. Positive symptoms fail however to respond to glutamatergic medication.

A commonly known side effect associated with schizo-affective patients known as akathisia (mistaken for schizophrenic symptoms) was found to be associated with increased levels of norepinephrine. Data supports the efficacy of novel antipsychotics which deal with agonism of the NDMA glutamate receptors, associated with regulating uptake of norepinephrine, which in turn affects the trafficking of glutamate. This, as well as the data noting exacerbation of positive symptoms in users of norepinephrine-agonizing amphetamine, suggests that schizophrenia may in fact have a greater association with abnormal norepinephrine-reuptake kinetics and less with dopamine, which may in fact be responsible for a large part of the mechanism of glutamate release. It would be greatly beneficial for further research to be done in this area, particularly in the metabolism of various essential amino acids and their pro- and inhibitory effects on neurotransmitter balance.

There have also been findings of differences in the size and structure of certain brain areas in schizophrenia. A 2006 metaanlaysis of MRI studies found that whole brain and hippocampal volume are reduced and that ventricular volume is increased in patients with a first psychotic episode relative to healthy controls. The average volumetric changes in these studies are however close to the limit of detection by MRI methods, so it remains to be determined whether schizophrenia is a neurodegenerative process that begins at about the time of symptom onset, or whether it is better characterised as a neurodevelopmental process that produces abnormal brain volumes at an early age. In first episode psychosis typical antipsychotics like haloperidol were associated with significant reductions in gray matter volume, whereas atypical antipsychotics like olanzapine were not. Studies in non-human primates found gray and white matter reductions for both typical and atypical antipsychotics.

A 2009 meta-analysis of diffusion tensor imaging studies identified two consistent locations of reduced fractional anisotropy (roughly the level of organization of neural connections) in schizophrenia. The authors suggest that two networks of white matter tracts may be affected in schizophrenia, with the potential for "disconnection" of the gray matter regions which they link. During fMRI studies, greater connectivity in the brain's default network and task-positive network has been observed in patients diagnosed with schizophrenia, and may reflect excessive attentional orientation toward introspection and toward extrospection, respectively. The greater anti-correlation between the two networks suggests excessive rivalry between the networks.

Diagnosis

Schizophrenia is diagnosed based on criteria in either the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, version DSM-IV-TR, or the World Health Organization's International Statistical Classification of Diseases and Related Health Problems, the ICD-10. These criteria use the self-reported experiences of the person, and abnormalities in behavior reported by family members, friends or co-workers, followed by a clinical assessment by a mental health professional. As of 2009 there is no objective test.

Criteria

The ICD 10 criteria are typically used in European countries, while the DSM criteria are used in the United States and the rest of the world, as well as prevailing in research studies. The ICD-10 criteria put more emphasis on Schneiderian first-rank symptoms, although, in practice, agreement between the two systems is high.

According to the revised fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), to be diagnosed with schizophrenia, three diagnostic criteria must be met:

1. Characteristic symptoms: Two or more of the following, each present for much of the time during a one-month period (or less, if symptoms remitted with treatment).
   • Delusions
   • Hallucinations
   • Disorganized speech, which is a manifestation of formal thought disorder
   • Grossly disorganized behavior (e.g. dressing inappropriately, crying frequently) or catatonic behavior
   • Negative symptoms: Blunted affect (lack or decline in emotional response), alogia (lack or decline in speech), or avolition (lack or decline in motivation)

   If the delusions are judged to be bizarre, or hallucinations consist of hearing one voice participating in a running commentary of the patient's actions or of hearing two or more voices conversing with each other, only that symptom is required above. The speech disorganization criterion is only met if it is severe enough to substantially impair communication.

2. Social/occupational dysfunction: For a significant portion of the time since the onset of the disturbance, one or more major areas of functioning such as work, interpersonal relations, or self-care, are markedly below the level achieved prior to the onset.
3. Duration: Continuous signs of the disturbance persist for at least six months. This six-month period must include at least one month of symptoms (or less, if symptoms remitted with treatment).

If signs of disturbance are present for more than a month but less than six months, the diagnosis of schizophreniform disorder is applied. Psychotic symptoms lasting less than a month may be diagnosed as brief psychotic disorder, and various conditions may be classed as psychotic disorder not otherwise specified. Schizophrenia cannot be diagnosed if symptoms of mood disorder are substantially present (although schizoaffective disorder could be diagnosed), or if symptoms of pervasive developmental disorder are present unless prominent delusions or hallucinations are also present, or if the symptoms are the direct physiological result of a general medical condition or a substance, such as abuse of a drug or medication.

Differential

See also: Dual diagnosis

Psychotic symptoms may be present in several other mental disorders, including bipolar disorder, borderline personality disorder, drug intoxication and drug-induced psychosis. Delusions ("non-bizarre") are also present in delusional disorder, and social withdrawal in social anxiety disorder, avoidant personality disorder and schizotypal personality disorder. Schizophrenia is complicated with obsessive-compulsive disorder (OCD) considerably more often than could be explained by pure chance, although it can be difficult to distinguish obsessions that occur in OCD from the delusions of schizophrenia.

A more general medical and neurological examination may be needed to rule out medical illnesses which may rarely produce psychotic schizophrenia-like symptoms, such as metabolic disturbance, systemic infection, syphilis, HIV infection, epilepsy, and brain lesions. It may be necessary to rule out a delirium, which can be distinguished by visual hallucinations, acute onset and fluctuating level of consciousness, and indicates an underlying medical illness. Investigations are not generally repeated for relapse unless there is a specific medical indication or possible adverse effects from antipsychotic medication.

"Schizophrenia" does not mean dissociative identity disorder—formerly and still widely known as "multiple personalities"—despite the etymology of the word (Greek σχίζω = "I split").

Subtypes

The DSM-IV-TR contains five sub-classifications of schizophrenia, although the developers of DSM-5 are recommending they be dropped from the new classification:

• Paranoid type: Where delusions and hallucinations are present but thought disorder, disorganized behavior, and affective flattening are absent. (DSM code 295.3/ICD code F20.0)
• Disorganized type: Named hebephrenic schizophrenia in the ICD. Where thought disorder and flat affect are present together. (DSM code 295.1/ICD code F20.1)
• Catatonic type: The subject may be almost immobile or exhibit agitated, purposeless movement. Symptoms can include catatonic stupor and waxy flexibility. (DSM code 295.2/ICD code F20.2)
• Undifferentiated type: Psychotic symptoms are present but the criteria for paranoid, disorganized, or catatonic types have not been met. (DSM code 295.9/ICD code F20.3)
• Residual type: Where positive symptoms are present at a low intensity only. (DSM code 295.6/ICD code F20.5)

The ICD-10 defines two additional subtypes.

• Post-schizophrenic depression: A depressive episode arising in the aftermath of a schizophrenic illness where some low-level schizophrenic symptoms may still be present. (ICD code F20.4)
• Simple schizophrenia: Insidious and progressive development of prominent negative symptoms with no history of psychotic episodes. (ICD code F20.6)

Management

Main article: Management of schizophrenia

The primary treatment of schizophrenia is antipsychotic medications often in combination with psychological and social supports. Hospitalization may occur with severe episodes of schizophrenia. This can be voluntary or (if mental health legislation allows it) involuntary (called civil or involuntary commitment). Long-term inpatient stays are now less common due to deinstitutionalization, although can still occur. Following (or in lieu of) a hospital admission, support services available can include drop-in centers, visits from members of a community mental health team or assertive community treatment team, supported employment and patient-led support groups.

In many non-Western societies, schizophrenia may be treated with more informal, community-led methods only. Multiple international surveys by the World Health Organization over several decades have indicated that the outcome for people diagnosed with schizophrenia in non-Western countries is on average better there than for people in the West.

Three small randomized controlled trials indicate that regular exercise has a positive effect on the physical and mental health of those with schizophrenia.

Medication

Risperidone (trade name Risperdal) is a common atypical antipsychotic medication

The first line psychiatric treatment for schizophrenia is antipsychotic medication. These can reduce the positive symptoms of psychosis. Most antipsychotics take around 7–14 days to have their main effect. Currently available antipsychotics fail, however, to significantly ameliorate the negative symptoms, and the improvements on cognition may be attributed to the practice effect.

The choice of which antipsychotic to use is based on a number of factors including: benefits, risks, and costs. It is debatable whether as a class typical or atypical antipsychotics are better. Both have equal drop-out and symptom relapse rates when typicals are used at low to moderate dosages. With respect to side effects typical antipsychotics are associated with extrapyramidal side effects while atypicals are associated with considerable weight gain, diabetes and risk of metabolic syndrome. Clozapine is an effective treatment for the 20—30% of people who respond poorly to other drugs, but it has the potentially serious side effect of agranulocytosis in 1—4%.

Research has questioned the claim that atypical antipsychotics have fewer extrapyramidal side effects than typical antipsychotics, especially when the latter are used in low doses or when low potency antipsychotics are chosen. It remains unclear whether the newer antipsychotics reduce the chances of developing neuroleptic malignant syndrome, a rare but serious and potentially fatal neurological disorder most often caused by an adverse reaction.

Response of symptoms to medication is variable: treatment-resistant schizophrenia is a term used for the failure of symptoms to respond satisfactorily to at least two different antipsychotics. For other people who are unwilling or unable to take medication regularly, long-acting depot preparations of antipsychotics may be given every two weeks to achieve control.

Psycholosocial

Psychotherapy is also widely recommended and used in the treatment of schizophrenia, although services may often be confined to pharmacotherapy because of reimbursement problems or lack of training.

Cognitive behavioral therapy (CBT) is used to target specific symptoms and improve related issues such as self-esteem, social functioning, and insight. Although the results of early trials were inconclusive as the therapy advanced from its initial applications in the mid 1990s, CBT has become an effective treatment to reduce positive and negative symptoms of schizophrenia, as well as improving functioning. However, in a 2010 article in Psychological Medicine entitled, "Cognitive behavioral therapy for the major psychiatric disorder: does it really work?", Lynch, Laws and McKenna found that no trial employing both blinding and psychological placebo has found CBT to be effective in either reducing symptoms or preventing relapse in schizophrenia.

Another approach is cognitive remediation, a technique aimed at remediating the neurocognitive deficits sometimes present in schizophrenia. Based on techniques of neuropsychological rehabilitation, early evidence has shown it to be cognitively effective, with some improvements related to measurable changes in brain activation as measured by fMRI. A similar approach known as cognitive enhancement therapy, which focuses on social cognition as well as neurocognition, has shown efficacy.

Family therapy or education, which addresses the whole family system of an individual with a diagnosis of schizophrenia, has been consistently found to be beneficial, at least if the duration of intervention is longer-term. Aside from therapy, the effect of schizophrenia on families and the burden on carers has been recognized, with the increasing availability of self-help books on the subject. There is also some evidence for benefits from social skills training, although there have also been significant negative findings. Some studies have explored the possible benefits of music therapy and other creative therapies.

The Soteria model is alternative to inpatient hospital treatment using a minimal medication approach. It is described as a milieu-therapeutic recovery method, characterized by its founder as "the 24 hour a day application of interpersonal phenomenologic interventions by a nonprofessional staff, usually without neuroleptic drug treatment, in the context of a small, homelike, quiet, supportive, protective, and tolerant social environment." Although research evidence is limited, a 2008 systematic review found the programme equally as effective as treatment with medication in people diagnosed with first and second episode schizophrenia.

Prognosis

Main article: Prognosis of schizophrenia

John Nash, a US mathematician, began showing signs of paranoid schizophrenia during his college years. Despite having stopped taking his prescribed medication, Nash continued his studies and was awarded the Nobel Prize in 1994. His life was depicted in the 2001 film A Beautiful Mind.

Schizophrenia has great human and economics costs. It results in a decreased life expectancy of 12—15 years primarily due to its association with obesity, little exercise, and smoking while an increased rate of suicide playing a lesser role. Schizophrenia is known to be a major cause of disability with active psychosis ranked as the third-most-disabling condition after quadriplegia and dementia and ahead of paraplegia and blindness. Most people however live independently with community support.

There is a higher than average suicide rate associated with schizophrenia. This has been cited at 10%, but a more recent analysis of studies and statistics revises the estimate at 4.9%, most often occurring in the period following onset or first hospital admission. Several times more attempt suicide. There are a variety of reasons and risk factors.

World Health Organization studies have noted that individuals diagnosed with schizophrenia have much better long-term outcomes in developing countries (India, Colombia and Nigeria) than in developed countries (United States, United Kingdom, Ireland, Denmark, Czech Republic, Slovakia, Japan, and Russia), despite antipsychotic drugs not being widely available.

After long-term follow-up half of people with schizophrenia have a favourable outcome while 16% have a delayed recovery after an early unremitting course. More usually, the course in the first two years predicted the long-term course. Early social intervention was also related to a better outcome. The findings were held as important in moving patients, carers and clinicians away from the prevalent belief of the chronic nature of the condition. This outcomes on average however is worse than for other psychotic and psychiatric disorders. While a moderate number of people with schizophrenia were seen to remit and remain well; the review raised the question that some may not require maintenance medication.

A clinical study using strict recovery criteria (concurrent remission of positive and negative symptoms and adequate social and vocational functioning continuously for two years) found a recovery rate of 14% within the first five years. A 5-year community study found that 62% showed overall improvement on a composite measure of clinical and functional outcomes.

Epidemiology

Disability-adjusted life year for schizophrenia per 100,000 inhabitants in 2004.

  no data

  ≤ 185

  185–197

  197–207

  207–218

  218–229

  229–240

  240–251

  251–262

  262–273

  273–284

  284–295

  ≥ 295

Schizophrenia affects approximately 0.3—0.7% of people at some point in there life. It occurs 1.4 times more frequently in males than females and typically appears earlier in men—the peak ages of onset are 20–28 years for males and 26–32 years for females. Onset in childhood is much rarer, as is onset in middle- or old age. Despite the received wisdom that schizophrenia occurs at similar rates worldwide, its prevalence varies across the world, within countries, and at the local and neighbourhood level. It causes approximately 1% of worldwide disability adjusted life years. The rate of schizophrenia varies up to three fold depending on how it is defined.

History

Main article: History of schizophrenia

Accounts of a schizophrenia-like syndrome are thought to be rare in the historical record before the 1800s, although reports of irrational, unintelligible, or uncontrolled behavior were common. A detailed case report in 1797 concerning James Tilly Matthews, and accounts by Phillipe Pinel published in 1809, are often regarded as the earliest cases of the illness in the medical and psychiatric literature. Schizophrenia was first described as a distinct syndrome affecting teenagers and young adults by Bénédict Morel in 1853, termed démence précoce (literally 'early dementia'). The term dementia praecox was used in 1891 by Arnold Pick to in a case report of a psychotic disorder. In 1893 Emil Kraepelin introduced a broad new distinction in the classification of mental disorders between dementia praecox and mood disorder (termed manic depression and including both unipolar and bipolar depression). Kraepelin believed that dementia praecox was primarily a disease of the brain, and particularly a form of dementia, distinguished from other forms of dementia, such as Alzheimer's disease, which typically occur later in life.

The word schizophrenia—which translates roughly as "splitting of the mind" and comes from the Greek roots schizein (σχίζειν, "to split") and phrēn, phren- (φρήν, φρεν-, "mind")—was coined by Eugen Bleuler in 1908 and was intended to describe the separation of function between personality, thinking, memory, and perception. Bleuler described the main symptoms as 4 A's: flattened Affect, Autism, impaired Association of ideas and Ambivalence. Bleuler realized that the illness was not a dementia as some of his patients improved rather than deteriorated and hence proposed the term schizophrenia instead.

Molecule of chlorpromazine (trade name Thorazine), which revolutionized treatment of schizophrenia in the 1950s

In the early 1970s, the diagnostic criteria for schizophrenia was the subject of a number of controversies which eventually led to the operational criteria used today. It became clear after the 1971 US-UK Diagnostic Study that schizophrenia was diagnosed to a far greater extent in America than in Europe. This was partly due to looser diagnostic criteria in the US, which used the DSM-II manual, contrasting with Europe and its ICD-9. David Rosenhan's 1972 study, published in the journal Science under the title On being sane in insane places, concluded that the diagnosis of schizophrenia in the US was often subjective and unreliable. These were some of the factors in leading to the revision not only of the diagnosis of schizophrenia, but the revision of the whole DSM manual, resulting in the publication of the DSM-III in 1980.{subscription required}

The term schizophrenia is commonly misunderstood to mean that affected persons have a "split personality". Although some people diagnosed with schizophrenia may hear voices and may experience the voices as distinct personalities, schizophrenia does not involve a person changing among distinct multiple personalities. The confusion arises in part due to the literal interpretation of Bleuler's term schizophrenia. The first known misuse of the term to mean "split personality" was in an article by the poet T. S. Eliot in 1933. Treatment was revolutionized in the mid-1950s with the development and introduction of chlorpromazine.

Society and culture

Schizophrenia has increasingly gained attention among the general public and the scientific community. Indeed, the November 11, 2010 issue of Nature was devoted to the theme of schizophrenia.

Stigma

Social stigma has been identified as a major obstacle in the recovery of patients with schizophrenia. In a large, representative sample from a 1999 study, 12.8% of Americans believed that individuals with schizophrenia were "very likely" to do something violent against others, and 48.1% said that they were "somewhat likely" to. Over 74% said that people with schizophrenia were either "not very able" or "not able at all" to make decisions concerning their treatment, and 70.2% said the same of money management decisions. The perception of individuals with psychosis as violent has more than doubled in prevalence since the 1950s, according to one meta-analysis.

In 2002, the Japanese Society of Psychiatry and Neurology changed the term for schizophrenia from Seishin-Bunretsu-Byō　精神分裂病 (mind-split-disease) to Tōgō-shitchō-shō　統合失調症 (integration disorder) to reduce stigma, The new name was inspired by the biopsychosocial model, and it increased the percentage of cases in which patients were informed of the diagnosis from 36.7% to 69.7% over three years.

Economic burden

In the United States alone, the overall cost of schizophrenia was estimated to be $62.7 billion in 2002. These estimates include health care costs (e.g. outpatient, inpatient, drugs, and long-term care) and non-health care costs (e.g. law enforcement, reduced workplace productivity, and unemployment).

Cultural depictions

The book and film A Beautiful Mind chronicled the life of John Forbes Nash, a Nobel Prize-winning mathematician who was diagnosed with schizophrenia. The Marathi film Devrai (featuring Atul Kulkarni) is a presentation of a patient with schizophrenia. The film, set in Western India, shows the behavior, mentality, and struggle of the patient as well as his loved-ones. Other factual books have been written by relatives on family members; Australian journalist Anne Deveson told the story of her son's battle with schizophrenia in Tell Me I'm Here, later made into a movie. The book The Eden Express by Mark Vonnegut recounts his struggle with schizophrenia and his recovering journey.

Research

Prevention

There is some evidence that early interventions in those with a psychotic episode may improve short term outcomes but that there is little benefit after 5 years.

There are no reliable markers for the later development of schizophrenia although research is being conducted into how well a combination of genetic risk plus non-disabling psychosis-like experience predicts later diagnosis. People who fulfill the 'ultra high-risk mental state' criteria, that include a family history of schizophrenia plus the presence of transient or self-limiting psychotic experiences, have a 20–40% chance of being diagnosed with the condition after one year. The use of psychological treatments and medication has been found effective in reducing the chances of people who fulfill the 'high-risk' criteria from developing full-blown schizophrenia. However, the treatment of people who may never develop schizophrenia is controversial, in light of the side-effects of antipsychotic medication; particularly with respect to the potentially disfiguring tardive dyskinesia and the rare but potentially lethal neuroleptic malignant syndrome. The most widely used form of preventative health care for schizophrenia takes the form of public education campaigns that provide information on risk factors and early symptoms, with the aim to improve detection and provide treatment earlier for those experiencing delays. The new clinical approach early intervention in psychosis is a secondary prevention strategy to prevent further episodes and prevent the long term disability associated with schizophrenia.

Diagnostic controversies

See also: Social construction of schizophrenia

The scientific validity of schizophrenia, and its defining symptoms such as delusions and hallucinations, have been criticised. In 2006, a group of consumers and mental health professionals from the UK, under the banner of Campaign for Abolition of the Schizophrenia Label, argued for a rejection of the diagnosis of schizophrenia based on its heterogeneity and associated stigma, and called for the adoption of a biopsychosocial model. Other UK psychiatrists opposed the move arguing that the term schizophrenia is a useful, even if provisional concept.

Similarly, there is an argument that the underlying issues would be better addressed as a spectrum of conditions or as individual dimensions along which everyone varies rather than by a diagnostic category based on an arbitrary cut-off between normal and ill. This approach appears consistent with research on schizotypy, and with a relatively high prevalence of psychotic experiences, mostly non-distressing delusional beliefs, among the general public. In concordance with this observation, psychologist Edgar Jones, and psychiatrists Tony David and Nassir Ghaemi, surveying the existing literature on delusions, pointed out that the consistency and completeness of the definition of delusion have been found wanting by many; delusions are neither necessarily fixed, nor false, nor involve the presence of incontrovertible evidence.

Nancy Andreasen, a leading figure in schizophrenia research, has criticized the current DSM-IV and ICD-10 criteria for sacrificing diagnostic validity for the sake of artificially improving reliability. She argues that overemphasis on psychosis in the diagnostic criteria, while improving diagnostic reliability, ignores more fundamental cognitive impairments that are harder to assess due to large variations in presentation. This view is supported by other psychiatrists. In the same vein, Ming Tsuang and colleagues argue that psychotic symptoms may be a common end-state in a variety of disorders, including schizophrenia, rather than a reflection of the specific etiology of schizophrenia, and warn that there is little basis for regarding DSM’s operational definition as the "true" construct of schizophrenia. Neuropsychologist Michael Foster Green went further in suggesting the presence of specific neurocognitive deficits may be used to construct phenotypes that are alternatives to those that are purely symptom-based. These deficits take the form of a reduction or impairment in basic psychological functions such as memory, attention, executive function and problem solving.

The exclusion of affective components from the criteria for schizophrenia, despite their ubiquity in clinical settings, has also caused contention. This exclusion in the DSM has resulted in a "rather convoluted" separate disorder—schizoaffective disorder. Citing poor interrater reliability, some psychiatrists have totally contested the concept of schizoaffective disorder as a separate entity. The categorical distinction between mood disorders and schizophrenia, known as the Kraepelinian dichotomy, has also been challenged by data from genetic epidemiology.

An approach broadly known as the anti-psychiatry movement, most active in the 1960s, opposes the orthodox medical view of schizophrenia as an illness. Psychiatrist Thomas Szasz argues that psychiatric patients are individuals with unconventional thoughts and behavior that society diagnoses as a method of social control, and therefore the diagnosis of "schizophrenia" is merely a form of social construction. The Hearing Voices Movement argues that many people diagnosed as psychotic need their experiences to be accepted and valued rather than medicalized.

Further reading

• Bentall, Richard. Madness explained: psychosis and human nature. London: Allen Lane; 2003. ISBN 0-7139-9249-2.
• Dalby, J. Thomas. Mental disease in history: a selection of translated readings. Bern: Peter Lang; 1996. ISBN 0-8204-3056-0.
• Fallon, James H.. The Neuroanatomy of Schizophrenia: Circuitry and Neurotransmitter Systems. Clinical Neuroscience Research. 2003 [Retrieved 2008-07-07];3:77–107. doi:10.1016/S1566-2772(03)00022-7.
• Fleck, Stephen; Theodore Lidz; and Alice Cornelison. Schizophrenia and the family. New York: International Universities Press; 1985. ISBN 0-8236-6001-X.
• Keen TM. Schizophrenia: orthodoxy and heresies. A review of alternative possibilities. Journal of Psychiatric and Mental Health Nursing. 1999;6(6):415–24. doi:10.1046/j.1365-2850.1999.00237.x. PMID 10818864.
• Laing, Ronald D.. The divided self: an existential study in sanity and madness. New York: Penguin Books; 1990. ISBN 0-14-013537-5.
• Lenzenweger, M.F. (2010). Schizotypy and schizophrenia: The view from experimental psychopathology. New York: Guilford Press. ISBN 978-1-60623-865-3
• Noll, Richard. The Encyclopedia of Schizophrenia And Other Psychotic Disorders (Facts on File Library of Health and Living). New York: Facts on File; 2006. ISBN 0-8160-6405-9.
• Roazen, Paul nd Victor Tausk. Sexuality, war, and schizophrenia: collected psychoanalytic papers. New Brunswick, N.J., U.S.A: Transaction Publishers; 1991. ISBN 0-88738-365-3. (On the Origin of the 'Influencing Machine' in Schizophrenia.)
• Shaner A, Miller G, Mintz J. Schizophrenia as one extreme of a sexually selected fitness indicator [PDF]. Schizophr. Res.. 2004 [Retrieved 2008-07-07];70(1):101–9. doi:10.1016/j.schres.2003.09.014. PMID 15246469.
• Schizophrenia: the sacred symbol of psychiatry. New York: Basic Books; 1976. ISBN 0-465-07222-4.
• Walker Elaine, et al. Schizophrenia: Etiology and Course. Annual Review of Psychology. 2004;55:401–30. doi:10.1146/annurev.psych.55.090902.141950. PMID 14744221.

External links

• Template:Dmoz
• NPR: the sight and sounds of schizophrenia
• The current World Health Organisation definition of Schizophrenia
• Symptoms in Schizophrenia Film made in 1940 showing some of the symptoms of Schizophrenia.